Onconetix Dirección

Dirección controles de criterios 0/4

El CEO de Onconetix's es Ralph Schiess, nombrado en Dec 2023, tiene una permanencia de menos de un año. posee directamente un 1.21% de las acciones de la empresa, con un valor de $43.08K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 1.4 años, respectivamente.

Información clave

Ralph Schiess

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	1.2%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	1.5yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Jan 24

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Oct 11

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Aug 17

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Jul 20

Blue Water Vaccines: Estimates And Expectations

May 17

CEO

Ralph Schiess (45 yo)

less than a year

Permanencia

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	sin datos	1.21% $ 42.4k
Karina Fedasz	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Brian Price	Head of Technology Strategy	3.8yrs	US$126.48k	sin datos
Frank Jaeger	Senior VP of Marketing & Business Development	1.4yrs	sin datos	sin datos
Andrew Skibo	Global Head of Biologics Operations	3.1yrs	sin datos	sin datos
Theodore Yoho	Head of Business Development	3.1yrs	sin datos	sin datos
Ali Fattom	Head of Science & Discovery	1.8yrs	sin datos	sin datos
Jay Newmark	Chief Medical Officer	1.3yrs	sin datos	sin datos
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	sin datos	1.06% $ 37.1k
Donald Very	Senior VP of Commercial Research & Development	no data	sin datos	sin datos

1.4yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ONCO no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Rice	Member of Scientific Advisory Board	no data	sin datos	sin datos
Thomas Meier	Director	less than a year	sin datos	sin datos
James Sapirstein	Chairman & Lead Independent Director	2.4yrs	US$182.12k	0% $ 0
Ajit Singh	Independent Director	less than a year	sin datos	0.014% $ 490.8
Sunetra Gupta	Member of Scientific Advisory Board	no data	sin datos	sin datos
Simon Tarsh	Independent Director	1.9yrs	US$112.62k	0% $ 0
Timothy Ramdeen	Independent Non-Executive Director	1.5yrs	US$82.67k	0% $ 0

1.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ONCO no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Onconetix Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Recent updates

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

New major risk - Share price stability

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

CEO, President & Executive Chairman recently sold US$2.6m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

CEO, President & Executive Chairman notifies of intention to sell stock

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

Blue Water Vaccines: Estimates And Expectations

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Announces Board Changes

Less than half of directors are independent

Blue Water Vaccines, Inc. has completed an IPO in the amount of $19.999998 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad